恒瑞医药
(600276)
| 流通市值：2829.51亿 | | | 总市值：2831.64亿 |
| 流通股本：63.74亿 | | | 总股本：63.79亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,997,533,912.14 | 22,819,784,741.31 | 17,013,632,174.61 | 11,168,379,006.13 |
| 营业收入 | 5,997,533,912.14 | 22,819,784,741.31 | 17,013,632,174.61 | 11,168,379,006.13 |
| 二、营业总成本 | 4,412,916,241.65 | 18,214,152,501.77 | 13,258,786,705.29 | 8,728,806,054.53 |
| 营业成本 | 942,849,379.52 | 3,525,247,786.91 | 2,657,554,084.36 | 1,769,372,177.37 |
| 税金及附加 | 58,017,910.82 | 219,257,133.43 | 162,733,199.31 | 109,607,709.73 |
| 销售费用 | 1,764,255,987.33 | 7,577,175,913.92 | 5,408,551,279.64 | 3,678,445,960.99 |
| 管理费用 | 576,301,558.24 | 2,416,974,460.17 | 1,675,912,477.84 | 1,083,920,890.75 |
| 研发费用 | 1,220,126,943.52 | 4,953,887,105.16 | 3,725,494,952.85 | 2,331,280,536.64 |
| 财务费用 | -148,635,537.78 | -478,389,897.82 | -371,459,288.71 | -243,821,220.95 |
| 其中:利息费用 | - | 5,903,776.07 | 4,743,304.45 | 3,686,342.92 |
| 其中:利息收入 | 166,463,087 | 477,143,415.78 | 350,861,139.69 | 208,348,193.4 |
| 加:公允价值变动收益 | 7,337,738.03 | -58,256,927.73 | -35,768,271.23 | -27,623,041.85 |
| 加:投资收益 | 615,897.07 | -49,156,803.96 | -11,565,726.62 | -9,558,327.13 |
| 资产处置收益 | 1,622,081.66 | 3,162,510.78 | 4,533,235.75 | 2,607,859.52 |
| 资产减值损失(新) | 109,562.54 | -107,216,559.21 | -12,709,216.4 | - |
| 信用减值损失(新) | -12,975,584.53 | 17,254,496.2 | -3,072,103.28 | 16,287,698.25 |
| 其他收益 | 54,681,449.36 | 498,485,970.59 | 245,066,125.43 | 148,922,217.88 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,636,008,814.62 | 4,909,904,926.21 | 3,941,329,512.97 | 2,570,209,358.27 |
| 加:营业外收入 | 198,808.58 | 3,798,351.9 | 2,434,776.15 | 1,613,301.5 |
| 减:营业外支出 | 133,696,788.68 | 246,593,587.87 | 131,387,370.51 | 59,377,494.59 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,502,510,834.52 | 4,667,109,690.24 | 3,812,376,918.61 | 2,512,445,165.18 |
| 减:所得税费用 | 135,022,146.8 | 389,288,987.74 | 361,347,090.85 | 222,039,341.63 |
| 六、净利润 | 1,367,488,687.72 | 4,277,820,702.5 | 3,451,029,827.76 | 2,290,405,823.55 |
| 持续经营净利润 | 1,367,488,687.72 | 4,277,820,702.5 | 3,451,029,827.76 | 2,290,405,823.55 |
| 归属于母公司股东的净利润 | 1,368,929,247.85 | 4,302,435,930.05 | 3,473,779,150.73 | 2,308,265,047.72 |
| 少数股东损益 | -1,440,560.13 | -24,615,227.55 | -22,749,322.97 | -17,859,224.17 |
| (一)基本每股收益 | 0.21 | 0.68 | 0.55 | 0.36 |
| (二)稀释每股收益 | 0.21 | 0.68 | 0.55 | 0.36 |
| 八、其他综合收益 | -5,925,391.68 | 17,841,438.93 | 14,004,359.12 | 22,513,217.11 |
| 归属于母公司股东的其他综合收益 | -6,141,934.94 | 16,094,142.5 | 10,917,389.49 | 18,744,086.33 |
| 九、综合收益总额 | 1,361,563,296.04 | 4,295,662,141.43 | 3,465,034,186.88 | 2,312,919,040.66 |
| 归属于母公司股东的综合收益总额 | 1,362,787,312.91 | 4,318,530,072.55 | 3,484,696,540.22 | 2,327,009,134.05 |
| 归属于少数股东的综合收益总额 | -1,224,016.87 | -22,867,931.12 | -19,662,353.34 | -14,090,093.39 |
| 公告日期 | 2024-04-18 | 2024-04-18 | 2023-10-26 | 2023-08-19 |
| 审计意见(境内) | | 标准无保留意见 | | |